Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin

Urology

Volumn 47, Issue 6, 1996, Pages 807-812

  Indudhara, Ramaiah ^a   Novick, Andrew C ^a   Hodge, Ernest ^a   Goormastic, Marlene ^a   Papajcik, Doreen ^a   Mastroianni, Barbara ^a   Cook, Dan ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; LYMPHOBLAST ANTIBODY; METHYLPREDNISOLONE; POLYCLONAL ANTIBODY; PREDNISONE; THYMOCYTE ANTIBODY;

ARTICLE; CADAVER KIDNEY; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL;

EID: 0029938644     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00067-2     Document Type: Article

References (16)

1. Starzl TE, Marchioro TL, Porter KA, Iwasaki Y, and Cerilli GJ: The use of heterologous anti-lymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet 124: 301-308, 1967.
2. Najarian JS, Simmons RL, Gewurz H, Moberg A, Merkel F, and Moore GE: Anti-serum to cultured human lymphoblasts: preparation, purification and immunosuppressive properties in man. Ann Surg 170: 617-632, 1969.
3. Wechter WJ, Morrell RM, Bergan J, RosenbergJC, Turcotte J, and Schultz JR: Extended treatment with antithymocyte globulin (ATGAM) in renal allograft recipients. Transplantation 28: 365-367, 1979.
4. Condie RM, Waskosky KE, Hall BL, et al.: Efficacy of Minnesota anti-lymphoblast globulin in renal transplantation: a multi-center, placebo-controlled, prospective, randomized, double-blind study. Transplant Proc 17: 1304-1311, 1985.
5. Pescovitz MD, Book BK, Milgrom ML, Leapman SB, Petersen B, and Filo RS: Comparison of Minnesota anti-lymphoblast globulin and Upjohn anti-thymocyte globulin for induction immunosuppression of human renal allografts. Surgery 116: 811-818, 1994.
6. Toledo-Pereyra LH, Bergren C, Mittal VK, Whitten JI, Baskin S, and McNichol L: A prospective randomized comparison of anti-lymphoblast globulin versus anti-thymocyte globulin for cadaver kidney transplantation. Transplantation 40: 448-450, 1985.
7. Lum CT, Umen AJ, Kasiske B, Goerdt P, Heim-Duthoy KL, Andersen RC, Odland MD, Ney AL, Jacobs DM, Rao KV, et al: Clinical impact of replacing Minnesota antilymphocyte globulin with ATGAM. Transplantation 59: 371-376, 1995.
8. Shoskes DA, Hodge EE, Goormastic M, Goldfarb DA, and Novick AC: HLA matching determines susceptibility to harmful effects of delayed graft function in renal transplant recipients. Transplant Proc 27: 1068-1069, 1995.
9. Kaplan EL, and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
10. Peto R, and Peto J: Asymptotically efficient rank invariant test procedures. J Roy Stat Soc Series A 135: 185-198, 1972.
11. Cox DR. Regression models and life tables. J Roy Stat Soc Series B 34: 187-202, 1972.
12. Sheil AGR, Kelly GE, Mears D, May J, Johnson JR, Jbels LS, and Stewart JH: Antilymphocyte globulin in patients with renal allografts from cadaveric donors: Late results of a controlled trial. Lancet 2: 227-228, 1973.
13. Monaco AP, and Codish SD: Survey of the current status of the clinical use of antilymphocyte serum. Surg Gynecol Obstet 142: 417-426, 1976.
14. Najarian JS, Simmons RL, Condie RM, et al.: Seven year's experience with anti-lymphoblast globulin for renal transplantation. Ann Surg 184: 352-368, 1976.
15. Taylor HE, Ackman CFD, and Horowitz I: Canadian clinical trial of antilymphocyte globulin in human cadaver renal transplantation. Can Med Assoc J 115: 1205-1208, 1976.
16. Novick AC, Braun WE, Steinmuller D, Buszta, Greenstreet R, and Kiser W: A controlled randomized double-blind study of anti-lymphoblast globulin in cadaver renal transplantation. Transplantation 35: 175-179; 1983.